# TELA Bio, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/TELA Bio, Inc.). ## Overview TELA Bio, Inc. develops and commercializes biologic and synthetic surgical implant products used to reinforce soft tissue in hernia repair and plastic/reconstructive surgery. The company sells primarily in the United States through a direct sales force, with additional commercial activity in parts of Europe. ## Products & services • OviTex reinforced tissue matrix • OviTex PRS reinforced tissue matrix • OviTex IHR product configurations • Surgical product shipping and consignment fulfillment • Related soft-tissue reconstruction product distribution - **OviTex** (75%) — Reinforced tissue matrix products used in hernia and soft-tissue repair procedures. - **OviTex PRS** (20%) — Reinforced tissue matrix products used in plastic and reconstructive surgery. - **OviTex IHR** (3%) — A configuration of the OviTex platform used in specific hernia repair applications. - **Other product and distribution offerings** (2%) — Complementary surgical and wound-care related products distributed through partnerships. - OviTex reinforced tissue matrix - OviTex PRS reinforced tissue matrix - OviTex IHR product configurations - Surgical product shipping and consignment fulfillment - Related soft-tissue reconstruction product distribution ## Customers TELA Bio sells mainly to hospital accounts, where surgeons and purchasing teams decide which implant products are stocked and used in procedures. Its products are also accessed through consignment arrangements, group purchasing organizations, and integrated delivery networks that influence hospital adoption and purchasing access. - **U.S. hospital accounts** (primary) — Primary buyers that purchase OviTex and OviTex PRS for use in surgical procedures and inventory stocking. - **Surgeons and procedural users** (primary) — Clinical users who select the products for hernia, plastic, and reconstructive surgery. - **Group purchasing organizations** (secondary) — Contracting intermediaries that improve access to hospital accounts and standardize purchasing. - **Integrated delivery networks** (secondary) — Health-system buyers that can broaden access across multiple hospitals and facilities. - **European hospital and distributor channels** (emerging) — Smaller non-U.S. customers reached through sales representatives, contractors, and distributors. - Hospital accounts in the U.S. buy for surgical use and inventory stocking - Surgeons use the products in hernia and reconstructive procedures - GPOs help drive contract access and purchasing standardization - IDNs matter because they can expand hospital penetration across systems - European distributors and contractors support smaller overseas adoption ## Geography TELA Bio generates the vast majority of its revenue in the United States, where it maintains a direct sales force and the largest installed commercial footprint. It also has a smaller commercial presence in the United Kingdom and European Union, which broadens its addressable market but remains secondary to the U.S. business. - **United States** (85%) — Predominant market based on direct sales force and hospital accounts. - **Europe** (15%) — Smaller commercial footprint across the UK and EU. - U.S. is the core market and main revenue source - 76 U.S. sales territories support hospital penetration - 15 European sales territories extend the platform abroad - UK and EU activity is smaller and more distributor-supported - GPO and IDN coverage is important to U.S. access ## Strategy TELA Bio is focused on expanding adoption of its OviTex platform by increasing hospital penetration, broadening procedure use within existing accounts, and improving sales-force productivity. It is also investing in product variations, longer shelf-life packaging, and lower-cost resorbable polymer-based devices to extend the platform and support future indications. - **Deepen adoption within existing hospital accounts** (short-term) — More procedures per account can raise utilization without relying only on new customer wins. - **Expand commercial access through GPOs and IDNs** (short-term) — Contract coverage can improve hospital access and reduce friction in purchasing decisions. - **Advance product development within the OviTex platform** (medium-term) — New configurations and enhancements can extend the product line and support broader clinical use. - **Broaden the soft-tissue reconstruction portfolio** (medium-term) — Adjacent technologies can diversify revenue sources and reduce dependence on a single product family. - Expand penetration across procedures in existing hospital accounts - Grow the direct sales force and improve territory productivity - Add GPO and IDN contracts to widen hospital access - Develop new OviTex configurations and packaging enhancements - Pursue adjacent soft-tissue reconstruction technologies ## Risks TELA Bio depends heavily on hospital adoption of a limited product family, so slower procedure growth or weaker purchasing conversion can affect revenue momentum. The business also faces execution risk from reimbursement, competitive surgical implant markets, inventory management, and reliance on third-party manufacturing and licensing arrangements. - **Dependence on OviTex product family** [high] — Most revenue has come from a small number of reinforced tissue matrix products, so demand weakness would have an outsized effect. - **Hospital adoption and purchasing cycle risk** [high] — Sales depend on surgeon preference, hospital contracting, and stocking decisions that can take time to convert. - **Macroeconomic and procedure-volume pressure** [medium] — Lower elective procedure activity or tighter hospital budgets can slow utilization and new account growth. - **Inventory excess and obsolescence** [medium] — If volume growth lags, the company may need to record additional excess and obsolete inventory charges. - **Supplier and license dependence** [high] — OviTex products are sourced under a license arrangement with Aroa, creating reliance on third-party economics and terms. - **Leverage and refinancing risk** [medium] — Debt maturities and interest obligations can constrain capital allocation and increase sensitivity to operating performance. - Revenue concentration in OviTex products creates product dependence - Hospital purchasing cycles can delay adoption and stocking decisions - Macroeconomic pressure may reduce procedure volumes or utilization - Inventory obsolescence risk rises if sales growth slows - Licensed supply terms create dependency on Aroa economics - Debt and covenant obligations add financial flexibility risk ## Accounting Revenue is recognized when control transfers, typically on shipment, but consignment arrangements shift recognition to the point of surgical use, which can create quarter-to-quarter timing differences. Investors should also watch inventory reserves, royalty and transfer-cost accounting under the Aroa arrangement, and debt-related interest and deferred financing cost amortization. - **Revenue recognition on shipment vs surgical use** — Point-in-time recognition with consignment exceptions - **Consignment inventory accounting** — Inventory and revenue timing - **Excess and obsolete inventory reserves** — Cost of revenue and inventory valuation - **Aroa license transfer-cost and royalty accounting** — Cost of revenue - **Debt financing costs and interest expense** — Interest expense and non-cash charges - Shipment-based revenue recognition can shift timing between quarters - Consignment sales are recognized when product is used in surgery - Shipping fees are recorded as revenue, affecting gross presentation - Inventory reserves matter if sales growth slows or product mix changes - Aroa transfer-cost and royalty terms affect cost of revenue - Debt interest and deferred financing costs affect reported losses --- *Last updated: 2026-04-29T05:01:35.492911+00:00*